Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 377 across all filing types
Latest filing 2022-05-17 AGM Information
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Verbale dei lavori dell'Assemblea Ordinaria degli Azionisti
AGM Information Classification · 100% confidence The document is a detailed verbale (minutes) of the Ordinary Shareholders' Meeting (Assemblea Ordinaria) of PHILOGEN S.p.A. held on April 27, 2022. It includes information about the meeting's convocation, attendees, voting procedures, agenda items including approval of the financial statements for the year ended December 31, 2021, remuneration policies, and board appointments. The document is a formal record of the proceedings and decisions made during the AGM. It is not a presentation, nor a report publication announcement, nor a financial report itself, but the official minutes of the AGM. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-05-17 Italian
Comunicato Stampa settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 99% confidence The document is titled "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program) and details the number of shares purchased by Philogen S.p.A. between May 9, 2022, and May 13, 2022, including daily transaction logs and total consideration. This activity directly corresponds to the definition of a company reporting transactions involving its own shares, which is classified as 'Transaction in Own Shares' (POS). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K) as it focuses solely on share repurchase activity, not comprehensive financial performance. It is a specific disclosure about share transactions, making POS the most accurate classification over the general 'Regulatory Filings' (RNS).
2022-05-16 Italian
The Board of Directors approves the net financial position for the first quarter of 2022
Earnings Release Classification · 99% confidence The document is a press release dated May 12, 2022, announcing that the Board of Directors approved the Group's net financial position as of March 31, 2022 (the first quarter). It includes a detailed table showing the Net Financial Debt comparison between March 31, 2022, and December 31, 2021, and provides updates on clinical trials. This content structure—financial position summary for a period shorter than a year, management commentary, and operational updates released shortly after the period end—is characteristic of an Interim/Quarterly Report (IR). It is not the full, audited Annual Report (10-K), nor is it just a brief Earnings Release (ER) or a simple announcement of a report (RPA). Q1 2022
2022-05-12 English
Il Consiglio Di Amministrazione approva la Posizione Finanziaria Netta relativa al Primo Trimestre 2022
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Philogen S.p.A. dated May 12, 2022, announcing the financial results (Net Financial Position) for the first quarter of 2022. It includes a detailed table of the Net Financial Position, management commentary on clinical trials (Nidlegy, Fibromun), and a certification by the financial reporting officer. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year (Q1), it qualifies as an Interim/Quarterly Report (IR). Q1 2022
2022-05-12 Italian
Comunicato Stampa settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 100% confidence The document title is "AGGIORNAMENTO SUL PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE" (Update on the Share Buyback Program). The content details the number of shares purchased by Philogen S.p.A. during a specific period (May 2 to May 6, 2022), including daily transaction breakdowns and total consideration. This activity directly relates to the company managing its own stock, which falls under the definition of 'Transaction in Own Shares' (share repurchase/issuance). The code for this is POS. The document is a formal announcement/report detailing the transaction, not just an announcement that a report is available (RPA/RNS).
2022-05-09 Italian
Allegato 3F - Aprile 2022
Transaction in Own Shares Classification · 98% confidence The document is titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI" / "MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER'S SECURITIES". It details transactions (purchases 'A') in the issuer's shares (PHILOGEN S.p.A.) over a specific period (April 2022). This structure is characteristic of mandatory regulatory filings reporting insider or related-party transactions in company stock. Reviewing the definitions, the category 'Director's Dealing' (Code: DIRS) covers reports of personal share transactions by directors and executives (insider trades). Although the document title is generic for transaction disclosure, the content strongly aligns with the intent of insider transaction reporting, which is often captured under DIRS or a similar transaction reporting code. Given the options, 'Transaction in Own Shares' (POS) typically refers to the company buying back its own stock, not necessarily director dealings. Since this document details transactions by the party identified in Section 1 (which is the Issuer itself, PHILOGEN S.p.A., but the context of these forms usually relates to insider/management transactions, or the issuer's own transactions), and it is a formal disclosure schema, it most closely matches the concept of reporting share transactions by insiders or related parties, which falls under DIRS, or if the issuer is transacting on its own behalf, POS. However, the structure strongly suggests a mandatory disclosure related to share dealings. Since the party listed in Section 1 is the Issuer itself, and Section 3 details the transactions, this is a report of the company's own transactions in its shares. Therefore, 'Transaction in Own Shares' (POS) is the most precise fit for the issuer reporting its own share operations, even if the form is used broadly.
2022-05-06 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.